Selection

Elanco Animal Health Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Tuesday, February 21, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, EBITDA, JAK, Cattle, North American Pet Health Insurance Association, ERP, Dog, Diabetes, Methane, GAAP, Farm Animal, Pressure, Research, Travel, FDA, Dermatology, Growth, Advertising, Tax, CER, Tyrosine kinase inhibitor, U.S. FDA, Sale, Bayer, Selection, Cat, Pig, Vaccine, Poultry, EPA, Pharmaceutical industry, Video game, Elanco

Asset impairment, restructuring, and other special charges were $32 million in the fourth quarter of 2022, compared to $110 million in the fourth quarter of 2021.

Key Points: 
  • Asset impairment, restructuring, and other special charges were $32 million in the fourth quarter of 2022, compared to $110 million in the fourth quarter of 2021.
  • Reported net interest expense was $62 million in the fourth quarter of 2022, a 13% increase as compared to the fourth quarter of 2021.
  • The adjusted effective tax rate was negative 22.0% in the fourth quarter of 2022 as compared to 19.2% in the fourth quarter of 2021.
  • Adjusted EBITDA was $174 million in the fourth quarter of 2022, a decrease of 19% compared to the fourth quarter of 2021.

Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

Retrieved on: 
Wednesday, February 22, 2023
Editas Medicine, CMO, Public expenditure, Patent, Gene editing, Bristol Myers Squibb, Ink, Selection, Shore, Collaboration, Health, IPSC, Tissue, Safety, Patient, BMS, Research, HSC, SCD, Paratriathlon, TDT, Pharmaceutical industry, Cryptocurrency

CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2022.

Key Points: 
  • In December 2022, Editas Medicine announced positive safety and efficacy data from the first two patients treated in the RUBY trial, suggesting clinical proof-of-concept.
  • Editas Medicine remains on track to dose the first patient in the Phase 1/2 EDITHAL trial for TDT in Q1 2023.
  • Editas Medicine plans to participate in the following investor events:
    The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m.
  • ET to provide and discuss a corporate update and financial results for the fourth quarter and full year of 2022.

Absolute Software Reports Second Quarter Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, February 14, 2023
Software, Technology, Internet, Security, Endpoint, Financial statement, IDC, Absolute, Consolidated, EDGAR, Ecosystem, Application, BlackBerry Unified Endpoint Manager, Adjustment, Absolute Software Corporation, Partnership, CAD, Selection, Lenovo, Bookkeeping, Cryptocurrency, Q2

Other revenue represents revenue derived from perpetual software licenses, non-recurring professional services and ancillary product lines, including consumer products.

Key Points: 
  • Other revenue represents revenue derived from perpetual software licenses, non-recurring professional services and ancillary product lines, including consumer products.
  • Refer to the “Use of non-IFRS measures and key metrics” section of the Q2 F2023 MD&A for further discussion of this measure.
  • Absolute Software will host a conference call on Tuesday, February 14, 2023 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss its results and business outlook.
  • The call will be accessible by dialing 1-844-282-4856 or 1-412-317-5627; participants should ask to join the Absolute Software call.

1-800-FLOWERS.COM, Inc. Reports Fiscal 2023 Second Quarter Results

Retrieved on: 
Thursday, February 2, 2023
Wine & Spirits, Specialty, Catalog, Food, Beverage, Online Retail, Luxury, Retail, Delivery Services, Bank statement, Public expenditure, Gift, Automation, Uncertainty, Investment, Free cash flow, Transport, Holiday, FLWS, Acquisition, Consumer, EBITDA, Table, Nature, McCann, GAAP, Earnings before interest and taxes, 1-800-Flowers.com, Inc., Adjustment, International, Marketing, The Things, Environment, Depreciation, Selection, Cyber Monday, Tax, Gourmet Foods, Airline, Music, Pharmaceutical industry, Bank, Bookkeeping, Insurance

1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS), a leading provider of gifts designed to help inspire customers to give more, connect more, and build more and better relationships, today reported results for its Fiscal 2023 second quarter ended January 1, 2023.

Key Points: 
  • 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS), a leading provider of gifts designed to help inspire customers to give more, connect more, and build more and better relationships, today reported results for its Fiscal 2023 second quarter ended January 1, 2023.
  • Expands leadership position in personalized gifting marketplace through the acquisition of the Things Remembered® brand, which occurred after the second quarter ended.
  • Gross profit margin for the quarter was 41.0%, increasing 90 basis points as compared with 40.1% in the prior year period.
  • The Company is updating its Fiscal 2023 guidance based on its second quarter performance and the current economic environment.

Zayed Sustainability Prize Opens Submissions for 2024 Cycle

Retrieved on: 
Monday, January 23, 2023
Professional Services, Other Energy, Environment, Sustainability, Environmental Issues, Energy, Finance, Drinking water, Selection, Waxahachie Global High School, Awards ceremony, ICC East Asia-Pacific, Water, Prize, Student, United Arab Emirates, Selection Committee, Ministry of Industry and Advanced Technology (United Arab Emirates), Multimedia, Pharmaceutical industry, Clothing, Risk management, Film industry, Management, Health, Food

The Zayed Sustainability Prize, the UAE’s pioneering global award for recognising excellence in sustainability, has officially announced that the 2024 cycle is now open for submissions.

Key Points: 
  • The Zayed Sustainability Prize, the UAE’s pioneering global award for recognising excellence in sustainability, has officially announced that the 2024 cycle is now open for submissions.
  • View the full release here: https://www.businesswire.com/news/home/20230123005377/en/
    January 16, 2023: Winners of the 2023 Zayed Sustainability Prize stand on stage with global leaders.
  • Winners of the 2024 Zayed Sustainability Prize will be announced at an Awards Ceremony during the COP28 Climate Summit.
  • The Zayed Sustainability Prize is the UAE’s pioneering global award in sustainability and a tribute to the legacy of the late founding father of the UAE, Sheikh Zayed bin Sultan Al Nahyan.

Freshworks Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Tuesday, February 7, 2023
Marketing, GAAP, Tax, Net, ARR, Uncertainty, Checked tone, Customer, Sale, Table, Investment, USD, Exercise, Selection, EUR, Cryptocurrency, Bank, Reinsurance, Insurance

(3) Non-GAAP net loss per share was estimated assuming 290.2 million and 293.8 million weighted-average shares outstanding for the first quarter and full year 2023, respectively.

Key Points: 
  • (3) Non-GAAP net loss per share was estimated assuming 290.2 million and 293.8 million weighted-average shares outstanding for the first quarter and full year 2023, respectively.
  • Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.
  • We have provided a reconciliation of other GAAP to non-GAAP financial measures in the financial statement tables for our fourth quarter and full year 2022 non-GAAP results included in this press release.
  • We believe these non-GAAP measures provide investors consistency and comparability with our past financial performance and facilitate period-to-period comparisons of our operating results.

Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies

Retrieved on: 
Thursday, January 19, 2023
CRISPR, Economics, Editas Medicine, Ink, Macrophage, IPSC, Gene editing, IMac, Patient, Cancer, SAN, Selection, Acquisition, Fine chemical, Pharmaceutical industry

CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies and acquire Editas Medicine’s preclinical gene edited induced pluripotent stem cell (iPSC) derived natural killer cell (iNK) programs and related manufacturing technologies.

Key Points: 
  • and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies and acquire Editas Medicine’s preclinical gene edited induced pluripotent stem cell (iPSC) derived natural killer cell (iNK) programs and related manufacturing technologies.
  • Shoreline Biosciences is a private biopharmaceutical company developing next-generation cellular immunotherapies based on iPSCs utilizing proprietary iNK and macrophage (iMACs) platforms.
  • As part of the transaction, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors, as well as an additional iNK program under development and certain related manufacturing technologies.
  • Additionally, Editas Medicine is eligible to receive future development and commercial milestone and royalty payments for each of the iNK programs and for future programs engineered with the gene editing technologies.

Institute of Corporate Directors announces 2023 Fellowship Award recipients

Retrieved on: 
Thursday, January 19, 2023
Organization, Corporation, Conference, CNW, Institute of Corporate Directors, Education, Selection, United States Senate Select Committee on Intelligence, ICD, Management

TORONTO, Jan. 19, 2023 /CNW/ - The Institute of Corporate Directors (ICD) announced four senior corporate governance leaders as recipients of the 2023 ICD Fellowship Award .

Key Points: 
  • TORONTO, Jan. 19, 2023 /CNW/ - The Institute of Corporate Directors (ICD) announced four senior corporate governance leaders as recipients of the 2023 ICD Fellowship Award .
  • 2023 ICD Fellowship Award Recipients:
    "Being on a board is harder today than almost any time in Canada's modern history.
  • To date, 101 directors across Canada have received this award, including this year's recipients.
  • The awards will be presented at the Fellowship Awards Gala on June 14 in Montreal as part of the 2023 ICD National Director Conference .

Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy

Retrieved on: 
Tuesday, November 29, 2022
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, NCI, TIL, National Cancer Institute, TILS, Lymphocyte, Patient, CRADA, Potyvirus, Neoplasm, Selection, Cancer, NIH, Cooperative research and development agreement, Development, Immunotherapy, Pharmaceutical industry, Vaccine, Medical imaging, Turnstone

The combination of Selected TILs and viral immunotherapy have the potential to enhance the efficacy of TILs and to extend their benefit to patients with a broad array of solid tumors.

Key Points: 
  • The combination of Selected TILs and viral immunotherapy have the potential to enhance the efficacy of TILs and to extend their benefit to patients with a broad array of solid tumors.
  • I believe TIL therapy is one of the most exciting areas of modern research in the cancer arena, notes Dr. Abbot.
  • Turnstones combination strategies with TIL and viral immunotherapy are designed to improve TIL harvest and overcome the immunosuppressive tumor microenvironment for better trafficking and expansion of our Selected TILs.
  • Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.

ASML Supervisory Board changes announced

Retrieved on: 
Wednesday, November 23, 2022
Software, Supervisory board, CFO, Audit committee, Audit, PricewaterhouseCoopers, ASML Holding, Committee, FTE, National Executive Board of the Boy Scouts of America, ASML, Unilever, Selection, Agriculture, TomTom, Vopak, Carlsberg Group, Euronext Amsterdam, AGM, Management, Carlsberg

The Supervisory Board expresses its thanks to Gerard and Rolf-Dieter, who have served on the Supervisory Board since 2015, for their valuable contributions, in particular as Chairman of the Supervisory Board and Selection & Nomination Committee and as Chairman of the Audit Committee respectively.

Key Points: 
  • The Supervisory Board expresses its thanks to Gerard and Rolf-Dieter, who have served on the Supervisory Board since 2015, for their valuable contributions, in particular as Chairman of the Supervisory Board and Selection & Nomination Committee and as Chairman of the Audit Committee respectively.
  • The Supervisory Board intends to nominate Nils Andersen for appointment as a member of the Supervisory Board effective from the 2023 AGM, with the intention to elect him as Chairman following his appointment.
  • We are confident that the Supervisory Board will highly benefit from Nilss broad knowledge and leadership experience, said Annet Aris, Vice Chair of the Supervisory Board.
  • With his extensive experience at various multinational companies and his financial expertise, we are convinced that Jack will be a valuable contributor to the Supervisory Board, said Gerard Kleisterlee, Chairman of the Supervisory Board.